Connect with others who understand.

Sign up Log in
Resources
About MyMyelomaTeam
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

CarT

A MyMyelomaTeam Member asked a question πŸ’­
Virginia Beach, VA
November 24
β€’
View reactions
A MyMyelomaTeam Member

You will have to ask again for AI to recognize the new question.πŸ’•
Paula🌹

November 24
A MyMyelomaTeam Member

Abemca not mentioned as an option here?

November 24
A MyMyelomaTeam Member

Are you asking about CAR-T cell therapy for multiple myeloma? Here is some detailed information based on my knowledge base:

CAR-T Cell Therapy for Multiple Myeloma
- What It Is: CAR-T cell therapy involves genetically engineering a person's T cells to target and attack myeloma cells. The T cells are modified to express Show Full Answer

Are you asking about CAR-T cell therapy for multiple myeloma? Here is some detailed information based on my knowledge base:

CAR-T Cell Therapy for Multiple Myeloma:
- What It Is: CAR-T cell therapy involves genetically engineering a person's T cells to target and attack myeloma cells. The T cells are modified to express chimeric antigen receptors (CARs) that can recognize and bind to specific proteins on cancer cells.
- Process:
- T Cell Collection: T cells are harvested from the patient.
- Genetic Modification: The T cells are modified in a lab to express CARs.
- Expansion: The modified T cells are grown in large numbers.
- Infusion: The CAR-T cells are infused back into the patient.
- Preparation: Before receiving CAR-T cells, patients often undergo lymphodepletion, a chemotherapy treatment to make room for the new T cells.
- Duration: The entire process, from T cell collection to infusion, can take up to three weeks.

Carvykti (Ciltacabtagene Autoleucel):
- Approval: Carvykti is FDA-approved for treating relapsed or refractory multiple myeloma in adults who have tried at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- Mechanism: Carvykti targets the B-cell maturation antigen (BCMA) on myeloma cells.
- Type: It is a type of CAR-T cell therapy made from the patient's own T cells.

For more detailed information, you can visit the following links:
- Carvykti: [Carvykti (Ciltacabtagene autoleucel) for Myeloma](https://www.mymyelomateam.com/treatments/carvykti)
- CAR-T Cell Therapy: [CAR-T Cell Therapy for Multiple Myeloma: What Is It?](https://www.mymyelomateam.com/resources/car-t-c...)

If you have any more specific questions, feel free to ask!

November 24

Related content

View All

What To Expect With SCT

A MyMyelomaTeam Member asked a question πŸ’­
Spotsylvania, VA

How Long Before I Will Get My Core Muscles Back After Radiation To My Back, The Compression Fix And Broken Ribs From MM.

A MyMyelomaTeam Member asked a question πŸ’­
Nanticoke, PA

Anyone Else Out There Lonely? At Lot Of Times, It Feels Like It's Just Me And My Caregiver. I'm Looking For Friends. Anyone Game? 🩷

A MyMyelomaTeam Member asked a question πŸ’­
Las Vegas, NV
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in